ArticleCureus2026
Philadelphia Chromosome-Positive B-cell Acute Lymphoblastic Leukemia: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell acute lymphoblastic leukemia (B-ALL) with the Philadelphia translocation-positive genotype (Ph+) is a high-risk leukemia subtype in older adults, where comorbidity often limits the use of intensive management and complicates clinical decision-making. We present the case of a 77-year-old female with progressive fatigue, dizziness, dyspnea, and palpitations, whose laboratory evaluation revealed symptomatic anemia and circulating blast cells. Peripheral smear and flow cytometry confirmed B-ALL, and fluorescence in situ hybridization (FISH) demonstrated BCR-ABL translocation. Cardiac examination revealed preserved systolic function with valvular disease and pulmonary hypertension, influencing treatment selection. Following a multidisciplinary tumor board discussion, the patient underwent reduced-intensity induction with mini-CVD (cyclophosphamide, vincristine, and dexamethasone) combined with dasatinib and central nervous system prophylaxis. Subsequent bone marrow examination demonstrated no morphologic or immunophenotypic evidence of residual leukemia, consistent with morphologic remission. The patient experienced clinical and hematologic improvement and was discharged on continuous tyrosine kinase inhibitor therapy with close monitoring. This case highlights the diagnostic workup, multidisciplinary treatment planning, and early therapeutic response in an elderly patient with Ph+ B-ALL while comparing these findings with the current literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.